Open-market purchases of Rapport Therapeutics, Inc. (RAPP) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Oct 26, 2026 | Paul Steven MDirector | $974K | Added | |||
| Weighted avg $27.28 (range $26.87–$27.84). Part of a 6-insider cluster buy Oct 20–23 totalling ~$1.57M across: Paul $974K, Maraganore ~$249K, Ignelzi ~$144K, Young ~$100K, Silva ~$100K, Sanchez ~$98K. Post-buy: 477,642 direct + 77,380 indirect (via Paul Capital Strategy III Fund LLC). | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.